On Aug 5, 2025, Aurobindo Pharma shares slipped ~2%, reaching a day low of ₹1,068.00 at 10:10 AM, after opening at ₹1,073.65 on BSE. The fall in Aurobindo Pharma shares came after the release of results for the quarter ended June 30, 2025.
During Q1FY26, Aurobindo Pharma reported a growth of 4.0% YoY in revenue from operations to ₹7,868 crore, backed by the solid performance in Europe and other Growth Markets.
Revenue from US formulations saw a marginal decline of 1.9% YoY to ₹3,488 crore (USD 408 million), while Europe formulations posted a robust increase of 18.0% YoY to ₹2,338 crore (EUR 241 million). Revenue from Growth Markets rose 8.8% YoY to ₹772 crore (USD 90 million), and ARV revenue witnessed a significant surge of 55.2% YoY to ₹355 crore (USD 41 million). However, API revenue declined by 16.0% YoY to ₹916 crore (USD 107 million).
EBITDA before R&D stood at ₹1,947 crore, reflecting a healthy margin of 24.8%, while EBITDA before forex and other income came in at ₹1,603 crore, with a margin of 20.4%. R&D expenditure, including depreciation, was ₹367 crore, accounting for 4.7% of total revenue. During the period, the company received final approval for 14 ANDAs from the USFDA, including one that was previously tentatively approved. Net Profit stood at ₹824 crore.
Commenting on the Company’s performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company, said: “We started the year steadily, with our European business maintaining strong growth momentum and our core US business showing resilience despite temporary challenges from destocking and seasonal dynamics. Our disciplined execution, operational initiatives, and recent US acquisition strengthen our commercial footprint and accelerate growth potential.”
Also Read: Shree Cement Q1 FY26 Earnings Results: Profit Jumps 95% YoY; EBITDA Up 34%
Headquartered in Hyderabad, Aurobindo Pharma Limited is an integrated global pharmaceutical company that develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Aug 5, 2025, 10:41 AM IST
Sachin Gupta
Sachin Gupta is a Content Writer with 6+ years of experience in the stock market, including global markets like the US, Canada, and Australia. At Angel One, Sachin specialises in creating financial content that simplifies complex market trends. Sachin holds a Master's in Commerce, specialising in Economics.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
